Stock Market Sleeps On Stereotaxis MAGiC CE Mark
Portfolio Pulse from
Stereotaxis' MAGiC catheter has received CE Mark approval in Europe, potentially increasing revenue by $3k per procedure with high margins. FDA approval is anticipated by September, which could boost recurring revenue and stock momentum. The first order of GenesisX was announced, with future orders expected post-commercial launch.
February 14, 2025 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stereotaxis' MAGiC catheter received CE Mark approval, potentially increasing revenue by $3k per procedure with high margins. FDA approval expected by September could further boost stock momentum.
The CE Mark approval allows Stereotaxis to increase its revenue per procedure significantly, with high gross margins. The anticipation of FDA approval by September adds to the potential for increased stock momentum. The announcement of the first GenesisX order and the expected commercial launch further support a positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100